ERBUD S.A.

As of March 31, 2026, ERBUD S.A. carries a market capitalization of 319.12M, placing it among publicly traded companies globally. Its enterprise value stands at 721.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ERBUD S.A.'s next confirmed earnings release is scheduled for November 16, 2026.

As of March 31, 2026, ERBUD S.A. has 11.93M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.10, and the price-to-book ratio stands at 0.77.

As of March 31, 2026, ERBUD S.A. trades at an EV/EBITDA multiple of 28.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 721.60M versus a market cap of 319.12M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, ERBUD S.A. maintains a current ratio of 1.26, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 77.99, indicating elevated leverage, while an interest coverage ratio of 0.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, ERBUD S.A. posted a negative return on equity (ROE) of -9.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.06, reflecting losses generated across the asset base. The company generates approximately 1.33M in revenue per employee across its workforce of 2,331.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 15.04 indicates how many times ERBUD S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, ERBUD S.A. recorded 26.75M in income tax expense. The company reported a pretax loss of -6.20M and -41.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, ERBUD S.A.'s stock has declined approximately 20.34% over the past 52 weeks. The 50-day moving average sits at 21.90, while the 200-day moving average is 25.99.

Over the twelve months ended March 31, 2026, ERBUD S.A. generated 3.11B in revenue and converted that into -41.07M in net income, yielding earnings per share of -2.76. EBITDA reached 25.36M, while operating income came in at 16.98M.

As of March 31, 2026, ERBUD S.A. holds 167.86M in cash and equivalents against 430.76M in total debt, resulting in a net debt position of 125.64M. Total book value stands at 412.77M, with working capital of 278.31M providing operational flexibility.

ERBUD S.A. produced -64.36M in operating cash flow over the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, ERBUD S.A. posted a gross margin of 8.45, reflecting its pricing power and cost economics. The operating margin of 0.55 and net profit margin of -1.32 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, ERBUD S.A. paid dividends of 2.24 per share. The dividend payout ratio of -107.47 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -20.17: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 13.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ERBUD S.A. shareholders.

As of March 31, 2026, ERBUD S.A. has an Altman Z-Score of 2.03, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.